Physician profile
David Mark Davis
NPI 1730267717
$3,811.87
in general payments reported to CMS, 2019-2025
12 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $843 · 2021: $730 · 2022: $408 · 2023: $725 · 2024: $590 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,528.12 | 2021-2024 | Vraylar |
| Axsome Therapeutics, INC. | $745.42 | 2023-2025 | Auvelity |
| Bausch Health US, LLC | $530.92 | 2019-2025 | Aplenzin |
| Intuitive Surgical, INC. | $332.39 | 2020 | |
| Allergan, INC. | $257.43 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $121.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.65 | 2019 | |
| Adlon Therapeutics L.P. | $92.34 | 2020-2021 | |
| Brainsway USA INC | $45.19 | 2024 | Brainsway Deep Tms System |
| Merck Sharp & Dohme LLC | $16.27 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.89 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.